Exelixis
EXEL
#2109
Rank
S$9.81 B
Marketcap
$34.41
Share price
-1.53%
Change (1 day)
16.66%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Cash on Hand

Cash on Hand as of June 2024 : S$1.30 B

According to Exelixis's latest financial reports the company has S$1.30 B in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Exelixis - Cash on Hand chart (from 2000 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2023-12-31S$1.31 B-25.06%
2022-12-31S$1.75 B-11.34%
2021-12-31S$1.97 B24.04%
2020-12-31S$1.59 B39.19%
2019-12-31S$1.14 B21.34%
2018-12-31S$0.94 B82.11%
2017-12-31S$0.51 B-14.64%
2016-12-31S$0.60 B156.88%
2015-12-31S$0.23 B24.07%
2014-12-31S$0.19 B-37.95%
2013-12-31S$0.30 B-38.98%
2012-12-31S$0.50 B100.13%
2011-12-31S$0.25 B20.01%
2010-12-31S$0.20 B-26.55%
2009-12-31S$0.28 B-24.36%
2008-12-31S$0.37 B-3.9%
2007-12-31S$0.39 B43.14%
2006-12-31S$0.27 B10.84%
2005-12-31S$0.24 B8.15%
2004-12-31S$0.22 B-43.29%
2003-12-31S$0.40 B4.76%
2002-12-31S$0.38 B-8.62%
2001-12-31S$0.42 B116.09%
2000-12-31S$0.19 B1597.95%
1999-12-31S$11.48 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
S$4.91 B 276.67%๐Ÿ‡ฌ๐Ÿ‡ง UK
S$9.48 B 626.96%๐Ÿ‡ซ๐Ÿ‡ท France
S$14.78 B 1,033.13%๐Ÿ‡บ๐Ÿ‡ธ USA
S$8.66 B 563.97%๐Ÿ‡บ๐Ÿ‡ธ USA
S$12.11 B 828.24%๐Ÿ‡บ๐Ÿ‡ธ USA
S$33.18 B 2,442.42%๐Ÿ‡บ๐Ÿ‡ธ USA
S$9.24 B 608.68%๐Ÿ‡บ๐Ÿ‡ธ USA
S$36.94 M-97.17%๐Ÿ‡บ๐Ÿ‡ธ USA
S$0.10 B-92.28%๐Ÿ‡บ๐Ÿ‡ธ USA